Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Heart Of A Pipeline: Can Novartis Keep The Cardio Portfolio Beating?

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The challenge of a generation shift in cardiovascular drugs is not new for Novartis, but the upcoming phase-out of Diovan through 2012 looks more difficult. As the firm prepares to lose Diovan exclusivity, its pipeline reflects an attempt to reprise the time-honored big pharma strategy that carried it through the loss of Lotrel in 2007: mix major efforts to develop novel, first-in-class agents with a push to accelerate its already marketed brands
Advertisement

Related Content

Efficacy Supplement Numbers On The Rise As Industry Braces For Patent Cliff
Efficacy Supplement Numbers On The Rise As Industry Braces For Patent Cliff
No Sales Model Left Behind: Novartis Joins Firms In Changing Market Focus
Hypertensives May Get Class Outcome Labels; Industry Wary Of Broad Efficacy
Novartis Gets By With A Little Help From Its Hypertension Franchise
Bristol Vanlev OCTAVE Data: Angioedema Risk Suggests Second-Line Use

Topics

Advertisement
UsernamePublicRestriction

Register

PS004018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel